TEVA Pharmaceuticals and
Allergan overnight confirmed that
Teva will buy Allergan’s generic
drug business (PD yesterday), with
Teva also formally withdrawing its
rival offer for Mylan.
After the acquisition Teva will
have a commercial presence in 100
markets, with the company saying
it will “help eliminate inefficiencies
and duplications in the global
generics space”.
Teva will acquire Allergan’s Actavis
operations globally, the firm’s
generics R&D unit, the international
OTC commercial unit and its global
manufacturing operations.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jul 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.